Liquid Biopsy

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, discusses how diagnosis or biomarker testing of EGFR-mutated lung cancer has evolved.

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, highlights treatment options for EGFR-mutated lung cancer.

Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, spoke with Healio about treatments in the pipeline for EGFR-mutated lung cancer.

Charu Aggarwal, MD, MPH, spoke with Healio about a presentation she gave at this year’s Chemotherapy Foundation Symposium.

Hossein Borghaei, DO, MS, spoke with Healio about his important takeaways from the International Lung Cancer Congress.

The FDA approved FoundationOne Liquid CDx to be used as a companion diagnostic to identify MET exon 14 skipping in patients with metastatic non-small cell lung cancer, according to a company-issued press release.

An electronic, odor-based tool accurately distinguished pancreatic and ovarian cancer specimens from benign disease and control specimens by analyzing vapors emanating from blood samples, according to results of a small, preliminary study.

Liquid biopsy-driven rechallenge with panitumumab led to objective responses in about one-third of patients with metastatic colorectal cancer, according to results of the phase 2 CHRONOS study presented at the virtual ASCO Annual Meeting.

A novel risk-stratification model developed for noninvasive identification of T1 colorectal cancer may help avoid unnecessary surgeries for high-risk patients.

Plasma cell-free DNA integrity assessed prior to surgery accurately predicted achievement of pathologic complete response to neoadjuvant chemotherapy among patients with locally advanced breast cancer, according to study results.